TY - JOUR
T1 - Rare antibody-mediated and seronegative autoimmune encephalitis
T2 - An update
AU - Seery, Nabil
AU - Butzkueven, Helmut
AU - O'Brien, Terence J.
AU - Monif, Mastura
N1 - Funding Information:
NS has received conference fee sponsorship from Roche. TO has received support from the National Health and Medical Research Council , The National Institute of Neurological Disorders and Stroke and Monash University . He has been supported by research grants and consultancies to his institution from Eisai, UCB Pharma, Praxis Precision Medicines, BioGen and Supernus. MM has served on advisory board for Merck, has received speaker honoraria from Merck and Biogen. Her institution receives funding from Merck, Australian National Health Medical Research Council, Brain Foundation, Charles and Sylvia Viertel Foundation, and MS Research Australia. HB’s institution receives funding from Biogen, Roche, Merck and Novartis for speaker engagements, study steering and advisory committee service. He is on the editorial board of Multiple Sclerosis and Related Disorders and the Steering committee of the Brain Health Initiative (Oxford Health Policy Forum).
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/7
Y1 - 2022/7
N2 - Paralleling advances with respect to more common antibody-mediated encephalitides, such as anti-N-methyl-D-aspartate receptor (NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) Ab-mediated encephalitis, the discovery and characterisation of novel antibody-mediated encephalitides accelerated over the past decade, adding further depth etiologically to the spectrum of antibody-mediated encephalitis. Herein, we review the major mechanistic, clinical features and management considerations with respect to anti-γ-aminobutyric acid B (GABAB)-, anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropinoic receptor- (AMPAR), anti-GABAA-, anti-dipeptidyl-peptidase-like protein-6 (DPPX) Ab-mediated encephalitides, delineate rarer subtypes and summarise findings to date regarding seronegative autoimmune encephalitis.
AB - Paralleling advances with respect to more common antibody-mediated encephalitides, such as anti-N-methyl-D-aspartate receptor (NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) Ab-mediated encephalitis, the discovery and characterisation of novel antibody-mediated encephalitides accelerated over the past decade, adding further depth etiologically to the spectrum of antibody-mediated encephalitis. Herein, we review the major mechanistic, clinical features and management considerations with respect to anti-γ-aminobutyric acid B (GABAB)-, anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropinoic receptor- (AMPAR), anti-GABAA-, anti-dipeptidyl-peptidase-like protein-6 (DPPX) Ab-mediated encephalitides, delineate rarer subtypes and summarise findings to date regarding seronegative autoimmune encephalitis.
KW - Anti- GABA encephalitis
KW - Anti-AMPAR encephalitis
KW - Anti-DPPX encephalitis
KW - Anti-GABA encephalitis
KW - Rare ab-mediated encephalitis
KW - Seronegative autoimmune encephalitis
UR - http://www.scopus.com/inward/record.url?scp=85132452514&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2022.103118
DO - 10.1016/j.autrev.2022.103118
M3 - Review Article
C2 - 35595048
AN - SCOPUS:85132452514
SN - 1568-9972
VL - 21
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
IS - 7
M1 - 103118
ER -